Unlocking Potential: Ferroptosis Inhibitors as Promising Strategies for Ischemic Stroke Therapy

Ischemic stroke is responsible for a lot of mortality and disability and is primarily due to reduced blood flow to the brain, thus leading to oxidative stress, inflammation, and death of neuronal cells. Recent studies posit ferroptosis, which is known as an iron-dependent form of programmed cell death, as a major player in the pathophysiology of ischemic stroke. Ferroptosis occurs as a result of iron overload, excessive lipid peroxidation, and dysfunction of glutathione peroxidase 4 (GPX4), collectively putting brain cells at risk. This review will bring into light a lot of strategies that target ferroptosis, such as iron chelation, where deferoxamine is the most profound example, antioxidants like ferrostatins and vitamin E, and enzyme inhibitors involved in lipid metabolism. Apart from gene therapy, nanoparticle-based drug delivery also shows great promise in all the foregoing avenues that selectively target the ferroptosis pathways and improve drug delivery across the blood-brain barrier. These strategies are promising for neuroprotection; however, a challenge exists in terms of drug specificity, off-target effects, and limited clinical trials. Future research is required to navigate these therapeutic strategies for actual clinical application. The role of ferroptosis during ischemic stroke and therapeutic interventions directed at it can lead to the introduction of appointments to clinical practice that accelerate the recoveries and outcomes of patient care.